nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—artery—uterine cancer	0.134	0.249	CbGeAlD
Azilsartan medoxomil—AGTR1—myometrium—uterine cancer	0.0649	0.12	CbGeAlD
Azilsartan medoxomil—AGTR1—epithelium—uterine cancer	0.0509	0.0944	CbGeAlD
Azilsartan medoxomil—AGTR1—uterine cervix—uterine cancer	0.0505	0.0936	CbGeAlD
Azilsartan medoxomil—AGTR1—smooth muscle tissue—uterine cancer	0.0491	0.091	CbGeAlD
Azilsartan medoxomil—AGTR1—decidua—uterine cancer	0.0481	0.0892	CbGeAlD
Azilsartan medoxomil—AGTR1—renal system—uterine cancer	0.0472	0.0876	CbGeAlD
Azilsartan medoxomil—AGTR1—female reproductive system—uterine cancer	0.0378	0.0702	CbGeAlD
Azilsartan medoxomil—AGTR1—vagina—uterine cancer	0.0342	0.0635	CbGeAlD
Azilsartan medoxomil—AGTR1—lymph node—uterine cancer	0.0221	0.041	CbGeAlD
Azilsartan medoxomil—Blood creatinine increased—Medroxyprogesterone Acetate—uterine cancer	0.0145	0.0314	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Etoposide—uterine cancer	0.013	0.0281	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Etoposide—uterine cancer	0.0122	0.0266	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Progesterone—uterine cancer	0.0116	0.0252	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Progesterone—uterine cancer	0.0116	0.0252	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Progesterone—uterine cancer	0.0107	0.0232	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.0105	0.0229	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.0105	0.0228	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Progesterone—uterine cancer	0.00987	0.0214	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.0097	0.0211	CcSEcCtD
Azilsartan medoxomil—Angioedema—Progesterone—uterine cancer	0.00938	0.0204	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00895	0.0194	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00868	0.0188	CcSEcCtD
Azilsartan medoxomil—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.0085	0.0185	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Progesterone—uterine cancer	0.00822	0.0178	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Progesterone—uterine cancer	0.00814	0.0177	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00787	0.0171	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00745	0.0162	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00738	0.016	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Epirubicin—uterine cancer	0.00726	0.0158	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Progesterone—uterine cancer	0.00724	0.0157	CcSEcCtD
Azilsartan medoxomil—Fatigue—Progesterone—uterine cancer	0.00723	0.0157	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Epirubicin—uterine cancer	0.00686	0.0149	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Doxorubicin—uterine cancer	0.00672	0.0146	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00656	0.0142	CcSEcCtD
Azilsartan medoxomil—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00655	0.0142	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Doxorubicin—uterine cancer	0.00635	0.0138	CcSEcCtD
Azilsartan medoxomil—Asthenia—Progesterone—uterine cancer	0.00601	0.0131	CcSEcCtD
Azilsartan medoxomil—Pruritus—Progesterone—uterine cancer	0.00593	0.0129	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Progesterone—uterine cancer	0.00574	0.0124	CcSEcCtD
Azilsartan medoxomil—Dizziness—Progesterone—uterine cancer	0.00554	0.012	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Etoposide—uterine cancer	0.00548	0.0119	CcSEcCtD
Azilsartan medoxomil—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00545	0.0118	CcSEcCtD
Azilsartan medoxomil—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00537	0.0117	CcSEcCtD
Azilsartan medoxomil—Rash—Progesterone—uterine cancer	0.00529	0.0115	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Progesterone—uterine cancer	0.00528	0.0115	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.0052	0.0113	CcSEcCtD
Azilsartan medoxomil—Fatigue—Dactinomycin—uterine cancer	0.00511	0.0111	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Etoposide—uterine cancer	0.00505	0.011	CcSEcCtD
Azilsartan medoxomil—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00502	0.0109	CcSEcCtD
Azilsartan medoxomil—Nausea—Progesterone—uterine cancer	0.00498	0.0108	CcSEcCtD
Azilsartan medoxomil—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00479	0.0104	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00478	0.0104	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Epirubicin—uterine cancer	0.00458	0.00994	CcSEcCtD
Azilsartan medoxomil—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00451	0.00979	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00444	0.00964	CcSEcCtD
Azilsartan medoxomil—Asthenia—Dactinomycin—uterine cancer	0.00425	0.00923	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Doxorubicin—uterine cancer	0.00424	0.0092	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Etoposide—uterine cancer	0.00417	0.00904	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Dactinomycin—uterine cancer	0.00405	0.0088	CcSEcCtD
Azilsartan medoxomil—Rash—Dactinomycin—uterine cancer	0.00374	0.00811	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Etoposide—uterine cancer	0.0037	0.00804	CcSEcCtD
Azilsartan medoxomil—Fatigue—Etoposide—uterine cancer	0.0037	0.00802	CcSEcCtD
Azilsartan medoxomil—Nausea—Dactinomycin—uterine cancer	0.00352	0.00764	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Epirubicin—uterine cancer	0.00333	0.00723	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Epirubicin—uterine cancer	0.00332	0.00722	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Doxorubicin—uterine cancer	0.00308	0.00669	CcSEcCtD
Azilsartan medoxomil—Asthenia—Etoposide—uterine cancer	0.00308	0.00668	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Doxorubicin—uterine cancer	0.00308	0.00668	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Epirubicin—uterine cancer	0.00307	0.00666	CcSEcCtD
Azilsartan medoxomil—Pruritus—Etoposide—uterine cancer	0.00303	0.00658	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Etoposide—uterine cancer	0.00293	0.00637	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Doxorubicin—uterine cancer	0.00284	0.00616	CcSEcCtD
Azilsartan medoxomil—Dizziness—Etoposide—uterine cancer	0.00284	0.00615	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Epirubicin—uterine cancer	0.00283	0.00615	CcSEcCtD
Azilsartan medoxomil—Rash—Etoposide—uterine cancer	0.0027	0.00587	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Etoposide—uterine cancer	0.0027	0.00586	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Doxorubicin—uterine cancer	0.00262	0.00569	CcSEcCtD
Azilsartan medoxomil—Nausea—Etoposide—uterine cancer	0.00255	0.00553	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00249	0.0054	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Epirubicin—uterine cancer	0.00236	0.00512	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Epirubicin—uterine cancer	0.00233	0.00507	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.0023	0.005	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Doxorubicin—uterine cancer	0.00218	0.00473	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Doxorubicin—uterine cancer	0.00216	0.00469	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00208	0.0045	CcSEcCtD
Azilsartan medoxomil—Fatigue—Epirubicin—uterine cancer	0.00207	0.0045	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.00192	0.00417	CcSEcCtD
Azilsartan medoxomil—Fatigue—Doxorubicin—uterine cancer	0.00192	0.00416	CcSEcCtD
Azilsartan medoxomil—Asthenia—Epirubicin—uterine cancer	0.00172	0.00374	CcSEcCtD
Azilsartan medoxomil—Pruritus—Epirubicin—uterine cancer	0.0017	0.00369	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Epirubicin—uterine cancer	0.00164	0.00357	CcSEcCtD
Azilsartan medoxomil—Asthenia—Doxorubicin—uterine cancer	0.0016	0.00346	CcSEcCtD
Azilsartan medoxomil—Dizziness—Epirubicin—uterine cancer	0.00159	0.00345	CcSEcCtD
Azilsartan medoxomil—Pruritus—Doxorubicin—uterine cancer	0.00157	0.00342	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Doxorubicin—uterine cancer	0.00152	0.0033	CcSEcCtD
Azilsartan medoxomil—Rash—Epirubicin—uterine cancer	0.00152	0.00329	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Epirubicin—uterine cancer	0.00151	0.00329	CcSEcCtD
Azilsartan medoxomil—Dizziness—Doxorubicin—uterine cancer	0.00147	0.00319	CcSEcCtD
Azilsartan medoxomil—Nausea—Epirubicin—uterine cancer	0.00143	0.0031	CcSEcCtD
Azilsartan medoxomil—Rash—Doxorubicin—uterine cancer	0.0014	0.00304	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Doxorubicin—uterine cancer	0.0014	0.00304	CcSEcCtD
Azilsartan medoxomil—Nausea—Doxorubicin—uterine cancer	0.00132	0.00287	CcSEcCtD
